D
Amylyx Pharmaceuticals, Inc. AMLX
$3.63 -$0.045-1.23%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

12/31/2024 09/30/2024 06/30/2024 03/31/2024 12/31/2023
Revenue -77.06% -33.22% 55.71% 324.95% 1,612.94%
Total Other Revenue -- -- -- -- --
Total Revenue -77.06% -33.22% 55.71% 324.95% 1,612.94%
Cost of Revenue 48.88% 137.06% 138.03% 165.35% 59.29%
Gross Profit -162.22% -158.98% -66.97% 1,219.25% 406.09%
SG&A Expenses -39.30% -15.53% 14.02% 39.59% 48.16%
Depreciation & Amortization -- -- -- -- --
Other Operating Expenses -- -- -- -- --
Total Operating Expenses 17.58% 55.20% 74.55% 92.30% 52.96%
Operating Income -911.12% -3,422.89% -119.12% 47.76% 119.27%
Income Before Tax -656.45% -4,620.35% -129.99% 55.79% 127.48%
Income Tax Expenses -107.82% -48.52% 58.10% 1,087.34% 549.35%
Earnings from Continuing Operations -712.42% -14,232.14% -127.80% 52.27% 124.84%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income -712.42% -14,232.14% -127.80% 52.27% 124.84%
EBIT -911.12% -3,422.89% -119.12% 47.76% 119.27%
EBITDA -886.73% -3,912.70% -119.99% 48.31% 119.86%
EPS Basic -705.81% -42,510.00% -100.06% 57.89% 121.36%
Normalized Basic EPS -795.39% -11,279.09% -108.16% 55.64% 119.14%
EPS Diluted -734.56% -16,371.12% -97.18% 56.86% 120.37%
Normalized Diluted EPS -823.85% -49,272.00% -106.26% 54.66% 118.38%
Average Basic Shares Outstanding 1.41% 1.73% 4.97% 8.43% 14.95%
Average Diluted Shares Outstanding -2.63% -1.08% 3.73% 9.42% 19.72%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --
Weiss Ratings